AUTHORS
Reem Karmali, MD, Carlos Galvez, MD2, Yuefan Huang, PhD3, Antony Tin, PhD4, J. Bryce Ortiz, PhD5, Radhakrishnan Ramchandren, MD6, Minetta C Liu, MD7, George P Koulogeorgas8, Jane N Winter, MD9, Yangruijue Ma, MS10, Ruohui Chen, PhD11, Bin Zhang, MD, PhD12, Ping Xie13, Shuo Ma, MD14, Nirav N. Shah, MD, MS15, Leo Gordon, MD16
AFFILIATIONS
1 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
2 University of Illinois at Chicago, Chicago, Illinois, United States
3 Natera, Inc., Austin, Texas, United States
4 Natera, Inc., Austin, Texas, United States
5 Natera, Inc., Austin, Texas, United States
6 Natera, Inc., Austin, Texas, United States
7 Natera, Inc., Austin, Texas, United States
8 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
9 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
10 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
11 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
12 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
13 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
14 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
15 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
16 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
ABSTRACT
Introduction: CAR T-cell therapy has revolutionized treatment for relapsed/refractory (R/R) aggressive B-cell lymphoma (aNHL), yet relapse remains common. Opportunities for improved outcomes include potentiating CAR-T activity with BTK inhibitors, that have demonstrated immunostimulatory properties, as well as utilizing strategies beyond imaging such as circulating tumor DNA (ctDNA)-based assessment to detect early molecular residual disease (MRD). We designed a single-arm, phase 2 multi-institutional study administering zanubrutinib as lead-in prior to apheresis (ZLI) followed by maintenance therapy (ZM) after CAR-T in patients (pts) with initial response to CAR-T. We previously reported a 6-month CR rate of 70% with this approach, meeting our primary endpoint. Here we present data with longer follow-up and results of serial ctDNA-based MRD dynamics and their association with clinical outcomes in this setting.
Methods: Thirty pts with R/R aNHL received zanubrutinib for 7 to 14 days prior to apheresis; zanubrutinib was held from apheresis through CAR-T infusion and restarted as maintenance for up to 12 months (mos) in pts achieving CR or PR at Day 29. Response was assessed by PET/CT using Deauville criteria, CR defined as Deauville score 1–3. Serial plasma samples were collected on Day 1 prior to ZLI and Day 8 of ZLI, post CAR-T on Day 29, 90, 180, 270, 365, 545 and 720 for pts with ZM. Tumor-specific variants were identified via whole genome sequencing (WGS) of tumor-normal pairs and were used to design a personalized multiplex assay to track ctDNA in plasma (SignateraTM Genome, Natera, Inc.) with results reported as mean tumor molecules per milliliter (MTM/mL). ctDNA dynamics and their association with response and survival outcomes were assessed in the 18 pts with samples available.
Results: Of the 30 pts who received ZLI and CAR-T, 23 also received ZM and were evaluable for survival outcomes with follow-up of 25.4 mos, 2-yr PFS and OS rates of 57% and 78% respectively. Eighteen pts had samples available for ctDNA analysis including: de novo DLBCL (n=10, 56%), transformed follicular (n=4, 22%), transformed marginal zone (n=3, 17%), and Richter transformation (n=1, 6%). Eight pts (44%) received bridging therapy (radiation, systemic therapy, or corticosteroids) prior to CAR-T infusion, 13 (72%) received ZM (median duration of 11.2 mos, range 2.1–12.3), and median follow-up was 17 mos (range 1–25). Five pts did not receive ZM due to lack of response, withdrawal, or inadequate platelet recovery. At baseline, median ctDNA levels were 402 MTM/mL (range 0.03–13,544). At Day 29 post-CAR-T, 11 pts (61%) achieved CR/CMR, 4 (22%) PR/PMR, and 3 (17%) had PD. At Day 180, 10 of 18 (56%) pts achieved CR/CMR. At last follow-up, 14 pts (78%) were alive and 11 (61%) remained in remission. Eleven of 18 pts (61%) had a decrease in ctDNA levels following ZLI, with a numerically higher Day 29 CR rate compared to pts with ctDNA increase (72.7% vs. 42.9%; OR 3.3, 95%CI 0.33–40.3; p=0.3), though this did not reach significance due to limited sample size.
Of 18 pts, 13 had a first post-CAR-T ctDNA timepoint available and were included in subsequent analyses. Stratifying by ctDNA fold change (FC) from day 1 (prior to lead-in) to first post-CAR-T (median log10 FC -4.25, range -12.13–+0.37), pts with greater ctDNA reduction (log10 FC at or below -4.25, n=7) had no progression events versus progression in 3 of 6 (50%) pts with lesser reduction, with median PFS of 18.2 mos (HR 11.08, 95%CI 1.01–1515; p=0.0489).
At Day 29, 5 pts (38%) were MRD-negative and 8 (62%) were MRD-positive. All 5 MRD-negative pts achieved imaging CR while all pts who did not achieve CR/CMR were MRD-positive. All MRD-negative pts remained progression-free while 3 of 8 MRD-positive pts progressed (37.5%; HR 4.26, 95%CI 0.41–574.06; p=0.26).
Conclusions: We demonstrate that reduction in ctDNA levels prior to CAR-T with Zanubrutinib improves depth and durability of response post-CAR-T. Additionally, ZM may potentiate ctDNA clearance post CAR-T. WGS-based ctDNA MRD monitoring captured clinically meaningful prognostic signals following CAR-T. While individual analyses were limited by sample size, findings were directionally consistent across time points and pre-to-post CAR-T ctDNA reduction was numerically associated with PFS. These data establish a rationale for larger prospective studies to validate ctDNA monitoring and define its role in post-CAR-T treatment decisions.
DISCLOSURES
Reem Karmali, MD: Kite/Gilead - Research Funding; AbbVie - Research Funding; Merck - Research Funding; Bristol Myers Squibb - Research Funding; AbbVie - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); AvenCell - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Miltenyi - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony)